Hemostemix 
HEM presently possesses the entirety of the intellectual property, which involves all the HS 12-01 2nd phase trial data and all the verified information from Hemostemix Israel.
HEM presently possesses the entirety of the intellectual property, which involves all the HS 12-01 2nd phase trial data and all the verified information from Hemostemix Israel.
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。